TY - JOUR
T1 - Adjuvant chemotherapy in patients with completely resected small cell lung cancer
T2 - A retrospective analysis of 26 consecutive cases
AU - Mizugaki, Hidenori
AU - Fujiwara, Yutaka
AU - Yamamoto, Noboru
AU - Yagishita, Shigehiro
AU - Kitazono, Satoru
AU - Tanaka, Ayako
AU - Horinouchi, Hidehito
AU - Kanda, Shintaro
AU - Nokihara, Hiroshi
AU - Tsuta, Koji
AU - Asamura, Hisao
AU - Tamura, Tomohide
PY - 2014/9
Y1 - 2014/9
N2 - Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.
AB - Objective: Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for small cell lung cancer patients retrospectively in clinical practice. Methods: From January 2002 to March 2012, 56 small cell lung cancer patients underwent surgery as initial therapy in our institute. Of these, 26 patients received adjuvant chemotherapy. The clinical data of patients who received adjuvant chemotherapy were retrospectively analyzed. Results: The chemotherapy regimens were cisplatin and irinotecan in 16 patients, cisplatin and etoposide in 1 and carboplatin and etoposide in 9. Median follow-up time was 44.8 months. Nineteen (73%) patients received the full course of chemotherapy. Median recurrence-free survival was 21.4 months. Median survival time was not reached. There was no treatment-related death. Conclusion: Adjuvant chemotherapy may be generally safe and efficacious in selected small cell lung cancer patients.
KW - Adjuvant chemotherapy
KW - Surgery
KW - small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84906850214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906850214&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyu092
DO - 10.1093/jjco/hyu092
M3 - Article
C2 - 25097183
AN - SCOPUS:84906850214
SN - 0368-2811
VL - 44
SP - 835
EP - 840
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 9
ER -
